Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 893-895, 2006; 10.1373/clinchem.2006.066605
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laika, B.
Right arrow Articles by Steimer, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laika, B.
Right arrow Articles by Steimer, W.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow General Clinical Chemistry
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2006;52:893-895.)
© 2006 American Association for Clinical Chemistry, Inc.

Letters to the Editor

ABCB1 (P-Glycoprotein/MDR1) Gene G2677T/A Sequence Variation (Polymorphism): Lack of Association with Side Effects and Therapeutic Response in Depressed Inpatients Treated with Amitriptyline

Barbara Laika, Stefan Leucht and Werner Steimera

Institute for Clinical Chemistry, and Pathobiochemistry, Munich University of Technology, Klinikum rechts der Isar, Munich, Germany

aAddress correspondence to this author at: Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, D-81675 Munich, Germany. Fax 49-89-4140-4875; e-mail W.Steimer@gmx.de.

The first 20% of the full text of this article appears below.


To the Editor:

Amitriptyline belongs to the class of tricyclic antidepressants (TCAs), which have been a cornerstone of antidepressive therapy for more than 4 decades. Despite being replaced by newer drugs in the United States, TCAs, and amitriptyline in particular, are still widely used in Europe and many parts of the world, where prescriptions for TCAs far outnumber those for newer, more expensive drugs.

Recently, we reported significant correlations between sequence variations in the genes that encode the metabolizing enzymes cytochrome P450 2D6 (CYP2D6) and 2C19 (CYP2C19), serum amitriptyline/nortriptyline concentrations, and adverse drug reactions in a population of 50 depressed inpatients (1)(2).

However, genetic variations in drug-metabolizing enzymes do not sufficiently explain the wide interindividual variations commonly observed in drug response and clinical outcome. Obviously, other genetic and environmental factors must be considered as well. The influence of sequence variations in the gene ATP-binding cassette, subfamily B (MDR/TAP), member 1 (ABCB1) on the . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Journal of Pharmacy PracticeHome page
M. J. Ehret
Pharmacogenomics of Antidepressant Medications
Journal of Pharmacy Practice, December 1, 2006; 19(6): 342 - 352.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.